GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA) to assess safety and tolerability

Trial Details

NCT ID
NCT05130255
Phase
PHASE1
Sponsor
Y-mAbs Therapeutics
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • GD2-SADA:177Lu-DOTA Complex
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Duarte, California, United States|34.13945,-117.97729
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Signed informed consent from patient, legal guardian(s) and/or adolescents obtained in accordance with local regulations. Pediatric patients must p…
  • Age ≥18 years at the time of informed consent, for High Risk Neuroblastoma \& sarcoma age ≥16 years of age at time of informed consent/assent
  • Measurable disease according to RECIST 1.1
  • ECOG performance status 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →